Welcome to the IKCEST

AIDS reviews | Vol.14, Issue.3 | | Pages 208-17

AIDS reviews

Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists.

Eva, Poveda Roger, Paredes Santiago, Moreno José, Alcamí Juan, Córdoba Rafael, Delgado Félix, Gutiérrez Josep M, Llibre Miguel, García Deltoro José, Hernández-Quero Federico, Pulido José Antonio, Iribarren Federico, García  
Abstract

The genotypic determination of HIV tropism to guide the use of maraviroc, the first CCR5 antagonist with specific antiviral activity against CCR5 (R5)-tropic HIV variants, has been widespread in the last two years. Retrospective analyses from maraviroc clinical trials (MOTIVATE and MERIT) demonstrated that specific genotypic tools and the phenotypic assay TrofileTM are comparable in predicting virologic response to maraviroc. Moreover, recent studies performed in cohorts of patients outside clinical trials have reported overall rates of virologic response to maraviroc up to 82% in patients harboring HIV R5-tropic variants according to genotypic tools. Specific technical requirements as well as recommendations for proper HIV tropism determination in the clinical setting have been improving, according to new data reported in several studies related with this issue. This review updates clinical and methodological recommendations for genotypic determination of HIV tropism to guide therapeutic decisions using CCR5 antagonists, considering the most recently reported data.

Original Text (This is the original text for your reference.)

Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists.

The genotypic determination of HIV tropism to guide the use of maraviroc, the first CCR5 antagonist with specific antiviral activity against CCR5 (R5)-tropic HIV variants, has been widespread in the last two years. Retrospective analyses from maraviroc clinical trials (MOTIVATE and MERIT) demonstrated that specific genotypic tools and the phenotypic assay TrofileTM are comparable in predicting virologic response to maraviroc. Moreover, recent studies performed in cohorts of patients outside clinical trials have reported overall rates of virologic response to maraviroc up to 82% in patients harboring HIV R5-tropic variants according to genotypic tools. Specific technical requirements as well as recommendations for proper HIV tropism determination in the clinical setting have been improving, according to new data reported in several studies related with this issue. This review updates clinical and methodological recommendations for genotypic determination of HIV tropism to guide therapeutic decisions using CCR5 antagonists, considering the most recently reported data.

+More

Cite this article
APA

APA

MLA

Chicago

Eva, Poveda Roger, Paredes Santiago, Moreno José, Alcamí Juan, Córdoba Rafael, Delgado Félix, Gutiérrez Josep M, Llibre Miguel, García Deltoro José, Hernández-Quero Federico, Pulido José Antonio, Iribarren Federico, García,.Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists.. 14 (3),208-17.

Disclaimer: The translated content is provided by third-party translation service providers, and IKCEST shall not assume any responsibility for the accuracy and legality of the content.
Translate engine
Article's language
English
中文
Pусск
Français
Español
العربية
Português
Kikongo
Dutch
kiswahili
هَوُسَ
IsiZulu
Action
Recommended articles

Report

Select your report category*



Reason*



By pressing send, your feedback will be used to improve IKCEST. Your privacy will be protected.

Submit
Cancel